Latest Advances in the Diagnosis and Management of Ocular Surface Disorders
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Ophthalmology".
Deadline for manuscript submissions: closed (1 July 2022) | Viewed by 1988
Special Issue Editors
Interests: ophthalmology; ocular surface disease; limbal stem cell transplantation; ophthalmic genetics; retinitis pigmentosa; adaptive optics imaging; clinical trials
2. Department of Ophthalmology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Interests: ophthalmology; cornea; ocular surface disease; dry eye disease; limbal stem cell transplantation; glaucoma
Special Issue Information
Dear Colleagues,
I am privileged to introduce this Special Issue on the “Latest Advances in the Diagnosis and Management of Ocular Surface Disorders”. The ocular surface plays a key role in maintaining corneal clarity, optimal vision, and ocular comfort. Alteration of the ocular surface integrity occurs in a wide range of entities and may lead to serious complications, including blindness. Dry eye disease (DED) is the most common cause of ocular complaints that not only causes visual disturbances, but also affects the quality of life and incurs a high economic burden. Limbal stem cell deficiency (LSCD), characterized by a corneal epithelial defect and vascularization, causes severe visual disability, and usually necessitates surgical intervention. Managing this can be challenging, especially in bilateral cases. Squamous neoplasia is relatively common in the ocular surface. Local/topical cytotoxic and immunomodulatory agents have been used successfully to manage ocular surface squamous neoplasia (OSSN), either as a sole treatment or as an adjuvant. The involvement of the ocular surface is common in immunologic disorders such as Stevens–Johnson syndrome (SJS) and mucus membrane pemphigoid (MMP). Both conditions result in a cicatrizing conjunctivitis that usually causes severe visual impairment.
The ocular surface field has evolved over the past few years. For instance, the pathogenesis and risk factors of DED have been investigated rigorously and several diagnostic methods and therapeutic strategies have been introduced. Bioengineered limbal and non-limbal stem cells have been used to treat LCSD and have shown promising outcomes. The use of immunomodulatory agents to treat OSSN has become popular, despite the controversies regarding the long-term outcome. Multiple immunosuppressive and immunomodulatory agents have been used to treat immunologic ocular surface disorders, with controversial results.
This Special Issue accepts reviews and original articles containing the latest advances in the diagnosis and management of ocular surface disorders, including, but not limited to, DED, meibomian gland dysfunction, blepharitis, ocular rosacea, LSCD, aniridia-associated keratopathy, ocular surface neoplasia, ocular surface immunologic disorders (including SJS, MMP, atopic, and allergic keratoconjunctivitis), recurrent corneal erosion, epithelial corneal dystrophies, and contact lens-related complications.
Dr. Danial Roshandel
Prof. Dr. Alireza Baradaran-Rafii
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dry eye disease
- meibomian gland dysfunction
- blepharitis
- limbal stem cell deficiency
- ocular surface neoplasms
- Stevens-Johnson syndrome
- mucus membrane pemphigoid
- atopic keratoconjunctivitis
- allergic keratoconjunctivitis
- recurrent corneal erosion
